Overview
- Description
The company's lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5).
- Website
- Country
- The Netherlands
- Sector
- Health Biotechnology
Engage with Leyden Laboratories*
*By clicking here you will be leaving the official EIC website and you will be directed to the Dealroom.co domain, an official EISMEA contractor for the EIC investor matchmaking platform.